In addition to Type-1 CD8+ T cells playing a crucial role in the efficacy of immunotherapy for cancer patients [25], Th1 CD4+ T cells also play a role in regulating antitumor protective efficacy, either by enhancing IFN-γ-mediated increase in MHC Class I expression and antigen-presenting capacity of DC and macrophages leading to the formation of effector/memory CD8 T cells or by dampening the immune response via the action of regulatory T cells [14, 27]. This evidence concerns the gene CD8A and cancer.